Navigation Links
New insights into the fate of anti-parasitics in manure and manured soils
Date:12/5/2007

In recent years, there has been growing interest in the question, if the entry of veterinary medicinal products (VMP) into soils via manure application is of environmental relevance. In a recent study, published in the November issue of the journal CLEAN, Kreuzig and co-workers now focused on the so far less investigated benzimidazole antiparasitics, adding valuable data to the so far available data set on fate and behavior of veterinary medicinal products in manure and manured soils.

An innovative experimental design for laboratory tests on VMP has been developed in order to simulate the real entry route of VMP into soil environments already under laboratory conditions. Degradation tests of VMP as 14C-labeled radiotracers in manures were conducted. On this basis, test manures containing 7-day aged VMP residues were prepared and then applied in laboratory batch tests to study degradation and sorption of VMP in manured soils. In further tests, the differentiation of microbial, chemical and photoinduced degradation were taken into account. Finally, test-plot experiments were performed under field conditions to monitor the transferability of the laboratory data to field conditions.

The benzimidazole antiparasitics flubendazole and fenbendazole mainly remained extractable in pig manure and soil samples. Antibiotics like sulfonamides, in contrast, rapidly formed non-extractable residues. Flubendazole was found unchanged while fenbendazole was accompanied by corresponding metabolites. Due to their slow degradation in pig manure, the manure storage is not considered to reduce substantially the environmental exposure. As shown by the sorption tests, both benzimidazoles did not fulfill the criteria of potential leachers. Finally, the degradation tests showed the dependence of the metabolic fate on the microbial activity in soil and on the test-manure application. These aspects, therefore, emphasized that the consideration of manure effects already under laboratory conditions supports a better understanding of the environmental fate of VMP under field conditions.


'/>"/>

Contact: Vera Koester
vkoester@wiley-vch.de
0049-620-160-6519
Wiley-Blackwell
Source:Eurekalert

Related biology technology :

1. Dental Implant Market Insights Webinar
2. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
3. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... RAFAEL, Calif., Feb. 23, 2017 ... U.S. dollars, except per share data, unaudited)Three Months Ended ... ChangeTotal BioMarin Revenue $   ...   22832%$ 1,117$   89026%Aldurazyme Net Product Revenue ... 906538%34823946%Naglazyme Net Product Revenue  ...
(Date:2/23/2017)... , Feb. 23, 2017  Seattle,s upscale Capitol Hill neighborhood, ... strange place for a head lice treatment salon to set ... a Tuscan restaurant and a French bistro on E Madison ... "We aren,t just any old lice clinic, we pride ourselves ... comfortable, and release some of the stigma associated with lice. ...
(Date:2/23/2017)... ... February 23, 2017 , ... Today, researchers can ... adiponectin, uric acid, and/or other biomarkers or SNPs of interest) using one, easy-to-collect ... SalivaLab , the relationship between insulin and other relevant biomarkers can be extensively ...
(Date:2/23/2017)... Washington, USA, and CARDIFF, UK (PRWEB) , ... ... ... the international society for optics and photonics , have been named Fellows of ... individual’s significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, ...
Breaking Biology Technology:
(Date:2/7/2017)... New York , February 7, 2017 ... as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or ... management and electronic transaction processing services, is pleased to ... of the Company. Effective January 31, 2017, ... the Board of Directors, CEO and President.  An experienced ...
(Date:2/2/2017)...   TapImmune, Inc. (NASDAQ: ... the development of innovative peptide and gene-based immunotherapeutics ... metastatic disease, announced today it has successfully completed ... second clinical lot of TPIV 200, the company,s ... manufactured vaccine product will be used to supply ...
(Date:1/31/2017)... 2017  Spero Therapeutics, LLC, a biopharmaceutical company ... of bacterial infections, today announced it has acquired ... Pro Bono Bio Ltd (PBB) to bolster its ... forms of Gram-negative bacteria.   The assets acquired have ... PBB group company. "The acquisition of ...
Breaking Biology News(10 mins):